Information Provided By:
Fly News Breaks for October 20, 2016
CELG
Oct 20, 2016 | 07:17 EDT
After attending the United European Gastroenterology Week annual meeting, Stifel analyst Katherine Breedis says key opinion leaders with whom she spoke were "very encouraged" by the data on Celgene's Crohn's treatment, GED-0301. The analyst thinks that the drug could be as successful as Celgene's successful Otezla psoriasis treatment. The analyst is upbeat on the outlook for Celgene's autoimmune drug portfolio, and she keeps a $138 price target and Buy rating on the shares.
News For CELG From the Last 2 Days
There are no results for your query CELG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.